{"nctId":"NCT00419744","briefTitle":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","startDateStruct":{"date":"2007-01"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":1200,"armGroups":[],"interventions":[{"name":"Budesonide/formoterol (SYMBICORT) pMDI","otherNames":[]},{"name":"Formoterol Turbuhaler","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A current clinical diagnosis of COPD with COPD symptoms for more than 2 years\n* Current smoker or smoking history of 10 or more pack years (1 pack year = 20 cigarettes smoked per day for one year)\n* A history of at least 1 COPD exacerbations requiring a course of steroids and/or antibiotics within 1-12 months before the first visit\n\nExclusion Criteria:\n\n* A history of asthma at or after 18 years of age\n* A history of allergic rhinitis at or after 18 years of age\n* Subjects taking oral steroids\n* Any significant disease or disorder that may jeopardize a subject's safety","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year","description":"Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null},{"groupId":"OG001","value":"0.84","spread":null},{"groupId":"OG002","value":"1.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Pre-dose Forced Expiratory Volume in 1 Second (FEV1)","description":"Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.18"},{"groupId":"OG001","value":"0.07","spread":"0.17"},{"groupId":"OG002","value":"0.04","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow (PEF)","description":"Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.82","spread":"37.96"},{"groupId":"OG001","value":"19.61","spread":"38.83"},{"groupId":"OG002","value":"15.81","spread":"41.43"}]}]}]},{"type":"SECONDARY","title":"Evening PEF","description":"Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.62","spread":"37.86"},{"groupId":"OG001","value":"17.77","spread":"37.67"},{"groupId":"OG002","value":"14.08","spread":"41.13"}]}]}]},{"type":"SECONDARY","title":"Dyspnea Symptom Scores","description":"Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.65"},{"groupId":"OG001","value":"-0.29","spread":"0.70"},{"groupId":"OG002","value":"-0.24","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication","description":"Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"3.57"},{"groupId":"OG001","value":"-1.03","spread":"3.74"},{"groupId":"OG002","value":"-0.28","spread":"3.60"}]}]}]},{"type":"SECONDARY","title":"St. George's Respiratory Questionnaire (SGRQ) Score","description":"Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.23","spread":"14.72"},{"groupId":"OG001","value":"-5.00","spread":"16.10"},{"groupId":"OG002","value":"-5.71","spread":"15.31"}]}]}]},{"type":"PRIMARY","title":"Rate of Exacerbations Per Subject-year","description":"Rate of exacerbations per subject-year","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.639","spread":null},{"groupId":"OG001","value":"0.745","spread":null},{"groupId":"OG002","value":"1.029","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79,"n":407},"commonTop":["Chronic Obstructive Pulmonary Disease","Headache","Nasopharyngitis","Bronchitis","Influenza"]}}}